Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) poses challenges for patients who decline blood products because of religious beliefs or other reasons. Despite potential curative prospects, many institutions refrain from offering alloHSCT to patients who decline blood products because of safety concerns associated with cytopenias.
Objectives: This review focuses on one institution's experience of conducting alloHSCT without blood components, emphasizing preparation and supportive care.
Methods: The approach of conducting alloHSCT without blood components, which involves ABO-compatible donor matching, nonmyeloablative regimens, and pretransplantation optimization of red blood cell production, is discussed.
Findings: The clinical team can minimize transfusion needs by using erythropoiesis-stimulating agents, thrombopoietin agonists, and peri- and post-transplantation management strategies. These recommendations can ensure patient safety and successful outcomes with bloodless medicine.
{"title":"Bloodless Medicine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.","authors":"Phyllis McKiernan, Eliana Baker, Melissa Baker","doi":"10.1188/24.CJON.463-468","DOIUrl":"https://doi.org/10.1188/24.CJON.463-468","url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (alloHSCT) poses challenges for patients who decline blood products because of religious beliefs or other reasons. Despite potential curative prospects, many institutions refrain from offering alloHSCT to patients who decline blood products because of safety concerns associated with cytopenias.</p><p><strong>Objectives: </strong>This review focuses on one institution's experience of conducting alloHSCT without blood components, emphasizing preparation and supportive care.</p><p><strong>Methods: </strong>The approach of conducting alloHSCT without blood components, which involves ABO-compatible donor matching, nonmyeloablative regimens, and pretransplantation optimization of red blood cell production, is discussed.</p><p><strong>Findings: </strong>The clinical team can minimize transfusion needs by using erythropoiesis-stimulating agents, thrombopoietin agonists, and peri- and post-transplantation management strategies. These recommendations can ensure patient safety and successful outcomes with bloodless medicine.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"463-468"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten
Background: About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).
Objectives: This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.
Methods: This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.
Findings: Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.
{"title":"Talazoparib Plus Enzalutamide in Patients With HRR-Deficient mCRPC: Practical Implementation Steps for Oncology Nurses and Advanced Practice Providers.","authors":"Jennifer Lloyd, Nazy Zomorodian, Geeta Devgan, Julia Batten","doi":"10.1188/24.CJON.483-491","DOIUrl":"10.1188/24.CJON.483-491","url":null,"abstract":"<p><strong>Background: </strong>About one-quarter of patients with advanced prostate cancer have alterations in homologous recombination repair (HRR) genes. In a global phase 3 study, talazoparib plus enzalutamide significantly improved progression-free survival in patients with HRR-deficient metastatic castration-resistant prostate cancer (mCRPC).</p><p><strong>Objectives: </strong>This article reviews the role of oncology nurses and advanced practice providers (APPs) in administering talazoparib plus enzalutamide in patients with mCRPC.</p><p><strong>Methods: </strong>This review and hypothetical case study illustrate the role of oncology nurses and APPs in the administration of talazoparib plus enzalutamide and the management of adverse events to ensure safe and effective use in clinical practice.</p><p><strong>Findings: </strong>Oncology nurses and APPs play an important role in the dosing and administration of talazoparib plus enzalutamide and can recognize and manage adverse events in patients with HRR-deficient mCRPC.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"483-491"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Oncology nurses and nurse practitioners often provide initial (prior to transition of care to a psychiatric provider) or maintenance assessment of and treatment for patients with depressed mood. Research informing oncology nu.
{"title":"Assessing and Treating Causes of Depressed Mood in Patients With Cancer.","authors":"Amber M Altidor","doi":"10.1188/24.CJON.443-448","DOIUrl":"https://doi.org/10.1188/24.CJON.443-448","url":null,"abstract":"<p><p>Oncology nurses and nurse practitioners often provide initial (prior to transition of care to a psychiatric provider) or maintenance assessment of and treatment for patients with depressed mood. Research informing oncology nu.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"443-448"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dan-Ni Wang, Li-Fang Lei, Jiao-Zhi Cai, Fu-Li Zhang, Hai-Xu Li, Hong Ye
Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of some chemotherapeutic agents. Effective treatment is limited.
Objectives: This single patient case details gua sha as an intervention to reduce CIPN.
Methods: A 38-year-old female patient received weekly treatment of gua sha in one-hour sessions for 10 weeks. The patient completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) subscale to describe her CIPN throughout and postintervention. A research assistant measured the extent of numbness or tingling along the limb from baseline to 18 months after gua sha. Descriptive data were used to summarize this case.
Findings: After gua sha, the total FACT/GOG-NTX subscale score increased from 13 to 36, indicating a sevenfold greater change than the minimum clinically important difference. The range of limb numbness and tingling decreased, and the symptoms remained stable during follow-up. Gua sha showed a positive clinical effect.
{"title":"Exploring Gua Sha Therapy for Chemotherapy-Induced Peripheral Neuropathy: A Single Case Report and Critical Analysis.","authors":"Dan-Ni Wang, Li-Fang Lei, Jiao-Zhi Cai, Fu-Li Zhang, Hai-Xu Li, Hong Ye","doi":"10.1188/24.CJON.E16-E26","DOIUrl":"10.1188/24.CJON.E16-E26","url":null,"abstract":"<p><strong>Background: </strong>Chemotherapy-induced peripheral neuropathy (CIPN) is a significant side effect of some chemotherapeutic agents. Effective treatment is limited.</p><p><strong>Objectives: </strong>This single patient case details gua sha as an intervention to reduce CIPN.</p><p><strong>Methods: </strong>A 38-year-old female patient received weekly treatment of gua sha in one-hour sessions for 10 weeks. The patient completed the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-NTX) subscale to describe her CIPN throughout and postintervention. A research assistant measured the extent of numbness or tingling along the limb from baseline to 18 months after gua sha. Descriptive data were used to summarize this case.</p><p><strong>Findings: </strong>After gua sha, the total FACT/GOG-NTX subscale score increased from 13 to 36, indicating a sevenfold greater change than the minimum clinically important difference. The range of limb numbness and tingling decreased, and the symptoms remained stable during follow-up. Gua sha showed a positive clinical effect.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"E16-E26"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: The use of herbal products, one component of the growing field of integrative cancer care, is a common yet controversial practice.
Objectives: This article distinguishes nursing issues specific to patient safety when herbal products are used during cancer treatment and identifies available evidence-based resources to enhance patient and professional comprehension.
Methods: PubMed®, CINAHL®, and Google Scholar™ databases were searched for literature published between 2018 and 2024 specific to the clinical sequelae of the use of herbal products and their interactions with antineoplastic drugs, as well as patient and healthcare providers' perceptions of efficacy and safety.
Findings: Patients have misconceptions about the use of herbal products and are generally unaware of these products' potential contraindications when taken in conjunction with antineoplastics. Providers seldom inquire about patients' use of these products and may lack knowledge of their potential interactions with prescription medicines.
{"title":"Herbal Products: Considerations and Educational Resources for Oncology Nurses.","authors":"Deborah A Boyle","doi":"10.1188/24.CJON.469-476","DOIUrl":"10.1188/24.CJON.469-476","url":null,"abstract":"<p><strong>Background: </strong>The use of herbal products, one component of the growing field of integrative cancer care, is a common yet controversial practice.</p><p><strong>Objectives: </strong>This article distinguishes nursing issues specific to patient safety when herbal products are used during cancer treatment and identifies available evidence-based resources to enhance patient and professional comprehension.</p><p><strong>Methods: </strong>PubMed®, CINAHL®, and Google Scholar™ databases were searched for literature published between 2018 and 2024 specific to the clinical sequelae of the use of herbal products and their interactions with antineoplastic drugs, as well as patient and healthcare providers' perceptions of efficacy and safety.</p><p><strong>Findings: </strong>Patients have misconceptions about the use of herbal products and are generally unaware of these products' potential contraindications when taken in conjunction with antineoplastics. Providers seldom inquire about patients' use of these products and may lack knowledge of their potential interactions with prescription medicines.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"469-476"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Celeste M Baldwin, Brandi W Fruin, Feliciana D Sales
Stress affects people's physiologic and mental well-being. Compounded stress from natural disasters, intergenerational trauma, stigma, and mistrust of the dominant society may lead to illness and potential oncologic disorde.
{"title":"Increasing Oncology Nurse Cultural Knowledge, Sensitivity, and Humility in Caring for the Native Hawai'ian and Pacific Islander Population.","authors":"Celeste M Baldwin, Brandi W Fruin, Feliciana D Sales","doi":"10.1188/24.CJON.506-511","DOIUrl":"10.1188/24.CJON.506-511","url":null,"abstract":"<p><p>Stress affects people's physiologic and mental well-being. Compounded stress from natural disasters, intergenerational trauma, stigma, and mistrust of the dominant society may lead to illness and potential oncologic disorde.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"506-511"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Advances in genomic science directly affect cancer care. Mastery of foundational concepts is necessary to understand the rationale for many aspects of cancer care, including prevention, surveillance, and treatment of malignan.
{"title":"Confusing Genomic Terms: The Importance of Being Precise.","authors":"Suzanne M Mahon, Patricia Friend, Susan Yackzan","doi":"10.1188/24.CJON.451-456","DOIUrl":"https://doi.org/10.1188/24.CJON.451-456","url":null,"abstract":"<p><p>Advances in genomic science directly affect cancer care. Mastery of foundational concepts is necessary to understand the rationale for many aspects of cancer care, including prevention, surveillance, and treatment of malignan.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"451-456"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Humans can form an intense bond with their pets through shared love, attachment, and amusement. Through this case study, nurses can develop an increased understanding of how companion pets affect the quality of life of patie.
{"title":"The Effects of Pets in Cancer Care: A Case Study.","authors":"Carrie Y Chong","doi":"10.1188/24.CJON.439-442","DOIUrl":"10.1188/24.CJON.439-442","url":null,"abstract":"<p><p>Humans can form an intense bond with their pets through shared love, attachment, and amusement. Through this case study, nurses can develop an increased understanding of how companion pets affect the quality of life of patie.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"439-442"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin
Background: Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.
Objectives: The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.
Methods: A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.
Findings: There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.
{"title":"Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial.","authors":"Francesca Boyte, Brighid Scanlon, Robyn Matthews, Elise Button, Lee Jones, Therese Hayes, Grant Partridge, Michael Smith, Glen Andrew Kennedy, Melissa Eastgate, Nicole Clare Gavin","doi":"10.1188/24.CJON.E9-E15","DOIUrl":"10.1188/24.CJON.E9-E15","url":null,"abstract":"<p><strong>Background: </strong>Monoclonal antibodies are widely used anticancer therapies. Increasing demand for ambulatory care necessitates exploration of efficiency measures.</p><p><strong>Objectives: </strong>The primary objective was to evaluate the impacts on chair time and associated cost of priming IV administration sets with a bolus of the prescribed monoclonal antibody drugs. A secondary objective was to assess the associated incidence of hypersensitivity reactions.</p><p><strong>Methods: </strong>A large tertiary hospital in Brisbane, Australia, conducted a randomized controlled trial (N = 128) with a two-arm design. Included monoclonal antibodies were daratumumab, obinutuzumab, pembrolizumab, and nivolumab.</p><p><strong>Findings: </strong>There was a statistically significant reduction in chair time for obinutuzumab, pembrolizumab, and nivolumab compared with the control. Findings suggest that this priming intervention reduces chair time and cost for some monoclonal antibody drugs. Future research could assess this practice in other oncology therapies.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"E9-E15"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Verification of pregnancy status prior to initiating radiation treatment for cancer is important to preserve patient and fetal safety. However, many institutions lack clear guidelines for pregnancy screening prior to treatmen.
{"title":"Implementing a Nurse-Driven Pregnancy Screening Protocol in the Radiation Oncology Setting.","authors":"Priyanka Devgan, Irawati Lam","doi":"10.1188/24.CJON.492-495","DOIUrl":"https://doi.org/10.1188/24.CJON.492-495","url":null,"abstract":"<p><p>Verification of pregnancy status prior to initiating radiation treatment for cancer is important to preserve patient and fetal safety. However, many institutions lack clear guidelines for pregnancy screening prior to treatmen.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":"28 5","pages":"492-495"},"PeriodicalIF":1.3,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}